Last reviewed · How we verify
Placebo of Hepalatide — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of Hepalatide (Placebo of Hepalatide) — Shanghai HEP Pharmaceutical Co., Ltd.. This is a placebo control formulation used in clinical trials and does not exert any active pharmacological effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of Hepalatide TARGET | Placebo of Hepalatide | Shanghai HEP Pharmaceutical Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of Hepalatide CI watch — RSS
- Placebo of Hepalatide CI watch — Atom
- Placebo of Hepalatide CI watch — JSON
- Placebo of Hepalatide alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of Hepalatide — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-hepalatide. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab